New Partnership: FCF Life Sciences & YAFO Capital

FCF Fox Corporate Finance and YAFO Capital (Shanghai) announce Joint Venture

Munich/Shanghai, June 17th, 2020 – The Life Sciences team at FCF Fox Corporate Finance is expanding its global network of strategic and capital investors with a new joint venture. Chinese investment and advisory firm YAFO Capital is the most recent addition to the roster of renowned international partners working with the Munich-based financing specialist. “Our joint venture with YAFO Capital will open up access to a huge pool of investors in China and throughout Asia, as our other partnerships have done for many years in regions such as the US,” says Arno Fuchs, CEO of FCF Fox Corporate Finance. “Now more than ever, Chinese investors are emerging as a key source of capital,” notes Dr. Mathias Schott, Director of FCF Life Sciences, “which makes this market an important factor in our efforts to help European Life Sciences enterprises attract global investors. By partnering with YAFO, FCF is taking another important step in this direction.”

Shanghai-based YAFO Capital specializes in bringing global Life Science technologies to Asia by way of financing, licensing or M&A deals. Thanks to FCF’s stellar connections in the European biotech industry, YAFO Capital stands to benefit from having a reliable partner on the ground in Munich with long-standing expertise in Life Science financing.

Sean Jiang, CEO & Founder of YAFO Capital, comments “We look forward to expanding our partnership with FCF and providing the best landing platform for European biopharma and medtech companies to access China. Over the last seven years, YAFO has built a solid institutional investor base and broad coverage of over 500 pharma, biotech, and medtech companies in Asia. We hope our investor base and expertise can benefit European companies when penetrating the Asian market.“

Building on the positive experiences and successes of their first joint pilot projects, the new venture will collaborate on business development initiatives in products and licensing, market research, joint road shows and, most importantly, key financing and strategic deals. “Our initial projects as partners have shown that we are in a good position to build a bridge to Asia for our Life Science clients in Europe – and that will continue to be the focus of our partnership moving forward,” Dr. Mathias Schott continues.

About FCF FOX CORPORATE FINANCE
FCF is a specialized Investment Bank and Financing Specialist, advising public and private
small/mid-market companies in the German speaking regions.

FCF focuses on four primary client segments:

• Mid-Markets: Medium-sized companies with sustainable business models in typical
  “Mittelstand” industries, such as industrial products and machinery, automotive,
  communications, logistics, and consumer products
• Real-Tech: R&D-driven companies in technology sectors, entering the
  commercialization stage with initial fast-growing revenues
• Growth: Fast growing companies, that have successfully entered their market,
  showing double digit revenue numbers and are seeking to expand widely
• Life Sciences: Highly innovative companies focusing on the development of cuttingedge
  biotechnology, med-tech, health-tech and pharmaceuticals solutions

FCF arranges, structures, and places equity and debt capital transactions and supports its
clients’ growth, IPO/Pre-IPO, acquisition and standard balance sheet (re-)financing strategies
at the best available terms.

Founded in 2005 and headquartered in Munich, FCF has direct relationships and works with
all leading German, European and international financiers, lenders and investment houses
addressing German small/mid-cap companies.

About YAFO Capital
Founded in 2013, YAFO Capital is a Shanghai-based investment and advisory boutique focused on Life Science. YAFO is dedicated to bringing global pharmaceutical and medical device products to China and the rest of Asia. Currently, with more than 20 experts working out of its offices in China, US, Japan and the UK, YAFO operates through its two divisions: YAFO Life Science (YLS, advisory) and YAFO Fund Management (AMAC licensed).

YAFO Life Science is the investment banking division of YAFO Capital with a focus on global biopharma that provides advisory services for Licensing, Capital Raising, and M&A.

YAFO ACCESS CHINA Forum – The most effective deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market. ACCESS CHINA creates invaluable BD opportunities by directly connecting and meeting with the right partners for development, licensing, and commercial collaborations.